MAM
FDMT icon

Martingale Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Martingale Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$110K Hold
11,775
– – ﹤0.01% 789
2025
Q4 		$88.3K Buy
11,775
+1,303
+12% +$13.2K ﹤0.01% 764
2025
Q3 		$91K Buy
+10,472
New +$62.6K ﹤0.01% 753

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Martingale Asset Management's FDMT Position: Q1 2026 in Review

Martingale Asset Management held its 4D Molecular Therapeutics (FDMT) position steady in Q1 2026 at 11,775 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #789.

Martingale Asset Management first reported a position in FDMT in Q3 2025 and has held it in 3 quarters since. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Martingale Asset Management held 11,775 shares of 4D Molecular Therapeutics worth $110K as of Q1 2026.
  • Martingale Asset Management left its 4D Molecular Therapeutics share count unchanged in Q1 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Martingale Asset Management's portfolio in Q1 2026, its #789 holding.
  • Martingale Asset Management first reported a position in 4D Molecular Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.